GlobalRPh RX List - IMAAVY
- Product / population
- Intravenous nipocalimab-aahu; selected product renal statement. No dialysis prescription supplied.
- Renal measure
- eGFR in mL/min/1.73 m2 in population pharmacokinetics.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
The source states that renal dose adjustment is unnecessary. However, no dedicated renal-impairment study was performed; the described population analysis found no important exposure difference at eGFR 30-89 mL/min/1.73 m2. Keep that evidence boundary visible rather than describing dialysis exposure as established. Other treatment precautions remain applicable.